- Home
- MGNI vs NVAX Comparison
MGNI vs NVAX Comparison
Compare MGNI & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNI
- NVAX
- Stock Information
- Founded
- MGNI 2007
- NVAX 1987
- Country
- MGNI United States
- NVAX United States
- Employees
- MGNI N/A
- NVAX N/A
- Industry
- MGNI Computer Software: Programming Data Processing
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGNI Technology
- NVAX Health Care
- Exchange
- MGNI Nasdaq
- NVAX Nasdaq
- Market Cap
- MGNI 2.4B
- NVAX 1.3B
- IPO Year
- MGNI N/A
- NVAX 1995
- Fundamental
- Price
- MGNI $24.13
- NVAX $6.38
- Analyst Decision
- MGNI Strong Buy
- NVAX Buy
- Analyst Count
- MGNI 13
- NVAX 5
- Target Price
- MGNI $20.85
- NVAX $16.60
- AVG Volume (30 Days)
- MGNI 2.4M
- NVAX 5.5M
- Earning Date
- MGNI 08-06-2025
- NVAX 08-07-2025
- Dividend Yield
- MGNI N/A
- NVAX N/A
- EPS Growth
- MGNI N/A
- NVAX N/A
- EPS
- MGNI 0.21
- NVAX 2.97
- Revenue
- MGNI $674,622,000.00
- NVAX $1,254,962,000.00
- Revenue This Year
- MGNI $0.32
- NVAX $56.85
- Revenue Next Year
- MGNI $11.02
- NVAX N/A
- P/E Ratio
- MGNI $111.90
- NVAX $2.12
- Revenue Growth
- MGNI 5.59
- NVAX 25.92
- 52 Week Low
- MGNI $8.22
- NVAX $5.01
- 52 Week High
- MGNI $24.46
- NVAX $17.81
- Technical
- Relative Strength Index (RSI)
- MGNI 77.05
- NVAX 44.45
- Support Level
- MGNI $17.90
- NVAX $6.26
- Resistance Level
- MGNI $20.85
- NVAX $6.66
- Average True Range (ATR)
- MGNI 0.69
- NVAX 0.33
- MACD
- MGNI 0.18
- NVAX -0.08
- Stochastic Oscillator
- MGNI 92.75
- NVAX 22.16
About MGNI Magnite Inc.
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.